Article: Gene therapy for hemophilia, a clinical viewpoint.
Journal of the Formosan Medical Association = Taiwan yi zhi
2023 Volume 122, Issue 11, Page(s) 1101–1110
Abstract: Gene therapy for hemophilia has been investigated for decades but no breakthroughs were made until Nathwani et al. achieved a significant and sustainable factor IX increase in hemophilia B patients in 2011. About eleven years later, in August 2022, the ... ...
| Abstract | Gene therapy for hemophilia has been investigated for decades but no breakthroughs were made until Nathwani et al. achieved a significant and sustainable factor IX increase in hemophilia B patients in 2011. About eleven years later, in August 2022, the first hemophilia A gene therapy product was approved by the European Commission and hemophilia treatment entered a new era. This review does not focus on the newest advances but rather the practical aspects of gene therapy aiming to provide an overview for physicians who treat hemophiliacs who did not participate in the clinical trials. The current status of gene therapy, focusing particularly on products likely to be clinically available soon, are reviewed and summarized. Currently, possible limitations of gene therapy are pre-existing neutralizing antibodies toward the vector, liver health, age, and inhibitor status. Possible safety concerns include infusion reactions, liver damage, and adverse effects from immune suppressants or steroids. In summary, generally speaking, gene therapy is effective, at least for several years, but the exact effect may be unpredictable and intensive monitoring for several months is needed. It can also be considered safe with careful practice on selected patients. In its current form, gene therapy will not replace all hemophilia treatments. Advances in non-factor therapy will also improve hemophilia care greatly in the future. We envisage that gene therapy may be included in multiple novel therapies for hemophilia and benefit some hemophilia patients while novel non-factor therapies may benefit others, together fulfilling the unmet needs of all hemophilia patients. |
|---|---|
| MeSH term(s) | Humans ; Hemophilia A/therapy ; Hemophilia A/drug therapy ; Hemophilia B/therapy ; Hemophilia B/drug therapy ; Factor IX/genetics ; Factor IX/therapeutic use ; Genetic Therapy/adverse effects ; Genetic Vectors |
| Chemical Substances | Factor IX (9001-28-9) |
| Language | English |
| Publishing date | 2023-05-18 |
| Publishing country | Singapore |
| Document type | Journal Article ; Review |
| ZDB-ID | 2096659-3 |
| ISSN | 1876-0821 ; 0929-6646 |
| ISSN (online) | 1876-0821 |
| ISSN | 0929-6646 |
| DOI | 10.1016/j.jfma.2023.05.008 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.B 1041: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.